These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 33516332

  • 1. Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply.
    Jacoby D, Ho CY, Lester SJ, Wang A, Olivotto I.
    Lancet; 2021 Jan 30; 397(10272):369-370. PubMed ID: 33516332
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy.
    Med Lett Drugs Ther; 2022 Jun 13; 64(1652):89-91. PubMed ID: 35657364
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-Term Effects of Mavacamten on Electromechanical Dispersion and Deformation in Obstructive Hypertrophic Cardiomyopathy.
    Del Franco A, Palinkas ED, Bellagamba CCA, Biagioni G, Zampieri M, Marchi A, Olivotto I.
    Circ Heart Fail; 2024 Mar 13; 17(3):e011188. PubMed ID: 38502728
    [No Abstract] [Full Text] [Related]

  • 10. [Mavacamten (Camzyos ®) : first myosin modulator for obstructive hypertrophic cardiomyopathy treatment].
    Lancellotti P, de Marneffe N, Scheen A.
    Rev Med Liege; 2024 Feb 13; 79(2):120-128. PubMed ID: 38356430
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy.
    Taddei-Allen P.
    J Manag Care Spec Pharm; 2022 Mar 13; 28(3):376-378. PubMed ID: 35199579
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy.
    Tower-Rader A, Ramchand J, Nissen SE, Desai MY.
    Expert Opin Investig Drugs; 2020 Nov 13; 29(11):1171-1178. PubMed ID: 32897741
    [Abstract] [Full Text] [Related]

  • 16. A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy.
    Burstein Waldman C, Owens A.
    Future Cardiol; 2021 Oct 13; 17(7):1269-1275. PubMed ID: 34018809
    [Abstract] [Full Text] [Related]

  • 17. [Mavacamten - the first disease-specific pharmacological treatment of hypertrophic cardiomyopathy].
    Magnusson P, Karason K.
    Lakartidningen; 2021 Aug 05; 118():. PubMed ID: 34498248
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Mavacamten: a promising new target drug for the treatment of hypertrophic cardiomyopathy].
    Zhang YP, He B.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Apr 24; 49(4):310-313. PubMed ID: 33874678
    [Abstract] [Full Text] [Related]

  • 20. Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten.
    Reza N, Dubey A, Carattini T, Marzolf A, Hornsby N, de Feria A, Mahmud N, Schuler P, Owens AT.
    JACC Heart Fail; 2024 Jun 24; 12(6):1123-1125. PubMed ID: 38661589
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.